The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

Background There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options.